1. Home
  2. FBGL vs IMNN Comparison

FBGL vs IMNN Comparison

Compare FBGL & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FBGL

FBS Global Limited Ordinary Shares

HOLD

Current Price

$1.09

Market Cap

11.3M

ML Signal

HOLD

Logo Imunon Inc.

IMNN

Imunon Inc.

HOLD

Current Price

$3.23

Market Cap

12.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FBGL
IMNN
Founded
1996
1982
Country
Singapore
United States
Employees
N/A
N/A
Industry
Miscellaneous manufacturing industries
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.3M
12.5M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
FBGL
IMNN
Price
$1.09
$3.23
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$182.61
AVG Volume (30 Days)
1.9M
33.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.41
$0.37
52 Week High
$1.20
$9.32

Technical Indicators

Market Signals
Indicator
FBGL
IMNN
Relative Strength Index (RSI) 63.45 40.05
Support Level $0.53 $3.01
Resistance Level $1.14 $4.07
Average True Range (ATR) 0.10 0.22
MACD 0.01 0.01
Stochastic Oscillator 68.05 23.73

Price Performance

Historical Comparison
FBGL
IMNN

About FBGL FBS Global Limited Ordinary Shares

FBS Global Ltd is a green building contractor and an established interior fit-out specialist in institutional, residential, commercial, and industrial building projects. As a green contractor focused on environmentally sound practices, the company aims to bid tenders for green building projects, use green construction methods and green materials for construction projects, including design, supply and installation of ceilings, partitions, timber deck, carpet, acoustic wall paneling, built-in furniture as well as mechanical and electrical services of a building. The company's revenue is derived mainly from the construction contracts and Sales of construction materials.

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Share on Social Networks: